Chloride transport modulators as drug candidates
Authors:
- 1 December 2021
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 321 (6) , C932-C946
Abstract
Chloride transport across cell membranes is broadly involved in epithelial fluid transport, cell volume and pH regulation, muscle contraction, membrane excitability, and organellar acidification. The human genome encodes at least 53 chloride-transporting proteins with expression in cell plasma or intracellular membranes, which include chloride channels, exchangers, and cotransporters, some having broad anion specificity. Loss-of-function mutations in chloride transporters cause a wide variety of human diseases, including cystic fibrosis, secretory diarrhea, kidney stones, salt-wasting nephropathy, myotonia, osteopetrosis, hearing loss, and goiter. Although impactful advances have been made in the past decade in drug treatment of cystic fibrosis using small molecule modulators of the defective cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, other chloride channels and solute carrier proteins (SLCs) represent relatively underexplored target classes for drug discovery. New opportunities have emerged for the development of chloride transport modulators as potential therapeutics for secretory diarrheas, constipation, dry eye disorders, kidney stones, polycystic kidney disease, hypertension, and osteoporosis. Approaches to chloride transport-targeted drug discovery are reviewed herein, with focus on chloride channel and exchanger classes in which recent preclinical advances have been made in the identification of small molecule modulators and in proof of concept testing in experimental animal models.Keywords
Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK072517)
- HHS | NIH | National Eye Institute (R01 EY013574)
- Telethon Foundation (TMLGCBC16TT)
- Cystic Fibrosis Foundation
This publication has 160 references indexed in Scilit:
- Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contractionProceedings of the National Academy of Sciences, 2012
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Potent, Metabolically Stable Benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR Inhibitors for Polycystic Kidney DiseaseJournal of Medicinal Chemistry, 2011
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Nanomolar Potency Pyrimido-pyrrolo-quinoxalinedione CFTR Inhibitor Reduces Cyst Size in a Polycystic Kidney Disease ModelJournal of Medicinal Chemistry, 2009
- Pharmacological “cross‐inhibition” of connexin hemichannels and swelling activated anion channelsGlia, 2008
- Expression Cloning of TMEM16A as a Calcium-Activated Chloride Channel SubunitCell, 2008
- Thiazolidinone CFTR inhibitors with improved water solubility identified by structure–activity analysisBioorganic & Medicinal Chemistry, 2008
- Nanomolar CFTR Inhibition by Pore-Occluding Divalent Polyethylene Glycol-Malonic Acid HydrazidesChemistry & Biology, 2008
- Molecular switch for CLC-K Cl − channel block/activation: Optimal pharmacophoric requirements towards high-affinity ligandsProceedings of the National Academy of Sciences, 2008